A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects

Exclusion Criteria

• - Any condition that, would interfere with the evaluation of the study drug or safety of subjects.
• - Subject has a known hypersensitivity to any components of the investigational product.
• - History of infection requiring hospitalization or treatment with IV antibiotics within 12 weeks before screening, or evidence of clinically significant active infection.
• - Subject has a history or present condition of malignancy.
• - Subject has a history or presence of drug addiction (urine test) or has alcohol consumption (breath test) of more than 21 (males) or 14 (females) units of alcohol per week.
• - Any blood donation or significant loss of blood within 56 days of study initiation,
• - Receipt of live (attenuated) vaccine within the 4 weeks before screening or during the study.